Navigation Links
Treating diabetes during pregnancy can break link to childhood obesity
Date:8/27/2007

igator at CHR Northwest and Hawaii, and the lead author of the study. "The key finding here is that the risk of overweight and obese children rises in step with higher levels of blood sugar during pregnancy. The good news for pregnant women is that by treating gestational diabetes, your children's risk of becoming overweight or obese drops considerably."

"My advice to pregnant women is three-fold: Discuss gestational diabetes screening with your doctor, usually between weeks 24 and 28 of pregnancy; if you have gestational diabetes, work with your physician to treat it, and stick with the treatment during your pregnancy. It's the best thing you can do to reduce your child's risk of obesity," said Dr. Hillier.

Funded by a grant from the American Diabetes Association, the study was made possible by Kaiser Permanente's interlinked, computerized databases. As the nation's largest and oldest integrated care delivery system, Kaiser Permanente researchers can anonymously review patient records dating back many years and look for connections with the patient's family members and other aspects of the members health.

The women in the study were screened during pregnancy for blood sugar level and gestational diabetes. The women's children were measured for weight between the ages of 5 and 7 the so-called "adiposity rebound" period, a strong predictor of adult obesity. The relationship between maternal blood sugar and childhood obesity was then analyzed.

Children of mothers with high levels of blood sugar who were untreated were 89 percent more likely to be overweight and 82 percent more likely to be obese by the time they were 5 to 7 years of age, compared to children whose mothers had normal blood sugar levels during pregnancy.

The obesity risk of children whose mothers had the highest blood sugar levelsand were treated for gestational diabeteswas not statistically different than children of mothers with normal blood sugar levels
'/>"/>

Contact: Danielle Cass
danielle.x.cass@kp.org
510-267-5354
Kaiser Permanente Division of Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gene Therapy shows promise in treating Hemophilia
2. Treating Depression In Children Could Lead To Poor Bone Development
3. Treating Epilepsy With Surgery
4. Treating Autism More Effectively
5. Stem Cell Therapy Effective For Treating Heart Attacks
6. Treating Leukemia With Natural Cells
7. Treating eye pain eases migraine
8. Treating wounds without stitches
9. Treating varicose veins
10. Treating acne with laser
11. Ketoconazole 2% more effective in treating Seborrheic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Robert J. Reilly, Joins Aethon Team, PITTSBURGH,...aethon.com ), the leading developer of mobile robo...nounced that Robert J. Reilly has,joined the compa...icer., Reilly, who was most recently Vice Preside...pecialty Pharmacy Division, brings more than 30,ye...
(Date:7/25/2008)...ce to be presented at Fenway Park ... /PRNewswire/ -- CVS/pharmacy announced today,that...llion in just 21 days,through its annual in-store ... seventh year of the annual fundraising effort whi...ALS research. This year,s fundraiser took,place in...
(Date:7/25/2008)...ng to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl...Now, researchers have some science to back up diet...: Most people do eat more on the weekend, even whe...ulgences can wreak havoc on weight control, either...
(Date:7/25/2008)...re an Olympian, Professional Athlete, Elite Amateu...ed to Know about Hydration to Boost Sports Perform... Marina del Rey, Calif. (V...are heading to Beijing following years of intense ...of capturing an Olympic medal and securing their p...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...lic supplements may not help reduce cholesterol or...lic consumed, says a new study//. Several earlier...ower cholesterol. However, researchers at Stanford...different garlic supplements on nearly 200 adults ...
...vehicles whiz past E.M. Bypass on the city's easte...left indicates the Kolkata Municipal Corporation's... Animals (PFA). It is here that the adage every ...ling pound aims to restore the mental and physical...
...earchers in Philadelphia have found a ground break...brought them to be able to trigger the Epstein-Bar...ntify patients whose infections can then be manipu...at this strategy could actually offer a novel way ...
... annual report for the year 2006 of the Internatio...to UN), suggests that abuse of prescriptions drugs...obe. The abuse of prescription drugs surpasses ...asy, cocaine and heroine in parts of Europe, Afric...
Other Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 2Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 3
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm.
The Storz Protege is an anterior segment unit only.
The CV-12000 provides the surgeon with all the options to perform today's newest techniques.
Phaco-emulsification systems CV series
Medicine Products: